Tyr1359

Site Information
KNCPGPVyRIMTQCW SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 1016332
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 ) , mutation of modification site ( 8 , 9 )
Disease tissue studied:	lung cancer ( 4 , 5 , 6 ) , non-small cell lung cancer ( 2 , 3 , 4 , 5 ) , non-small cell lung adenocarcinoma ( 3 , 4 , 5 )
Relevant cell line - cell type - tissue:	BaF3 ('B lymphocyte, precursor') ( 8 , 9 ) , Jurkat (T lymphocyte) ( 8 ) , lung ( 6 ) , NCI-H2228 (pulmonary) ( 3 ) , NCI-H3122 (pulmonary) ( 2 , 4 , 5 )

Downstream Regulation
Effects of modification on ALK:	molecular association, regulation ( 8 )
Effects of modification on biological processes:	cell growth, altered ( 8 )
Induce interaction with:	Src (human) ( 8 )

References
1	Emdal KB, et al. (2018) Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma. Sci Signal 11 30459283 Curated Info
2	Rikova K (2013) CST Curation Set: 18450; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954 Curated Info
3	Rikova K (2013) CST Curation Set: 18449; Year: 2012; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954 Curated Info
4	Possemato A (2011) CST Curation Set: 11908; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
5	Possemato A (2011) CST Curation Set: 11919; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
6	Hu Y (2010) CST Curation Set: 8706; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
7	Rikova K, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-203 18083107 Curated Info
8	Cussac D, et al. (2004) Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 103, 1464-71 14563642 Curated Info
9	Bai RY, et al. (2000) Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96, 4319-27 11110708 Curated Info